TACC2

Across TCGA pan-cancer cohorts, TACC2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated TACC2 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TACC2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TACC2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where TACC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.659	0.424	<.001	73	view →
COAD	DFS	Median	II,III,IV	1.000	0.911	.012	36	view →
LUAD	DFS	Tertile	II,III,IV	0.754	0.996	<.001	36	view →
GBM	DFS	Median	All	0.838	0.600	<.001	33	view →
HNSC	DFS	Median	All	0.983	0.903	.008	26	view →
LSCC	DFS	Quartile	II,III,IV	0.939	0.586	.017	15	view →
CCRCC	OS	Quartile	III,IV	0.901	0.579	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

TACC2–PDAC (OS)

Open the PDAC breakdown →